A new oncofetal antigen (OFA-1) has been identified on biopsied and cultured human tumors of diverse histologic origin including over 50% of 170 biopsied melanomas, sarcomas, and carcinomas. OFA-1 was not detected on any of 61 normal adult tissues, but was detected on fetal brain tissues by serologic absorption. OFA-1 was induced on normal fibroblasts after in vitro culture. OFA-1 is immunogenic in man, unlike other fetal antigens (CEA and AFP), since antibody to OFA-1 is found in sera of many cancer patients and is induced in cancer patients immunized with OFA-1 positive allogeneic tumor cells. Tumor associated antigens were isolated from melanoma cells cultured in a serum-free chemically defined medium. The purified antigens were cross-reactive with other melanomas, but not with sarcomas or fetal tissues. The purified antigen was labeled with 125I and used to develop a radioimmunoassay with melanoma patients' sera. The assay will be tested for sensitivity in detecting soluble antigen in sera from advanced cancer patients and a similar assay will be developed with the oncofetal antigen. We will continue to investigate antigenic modulation and other immune mechanisms that account for survival of antigenic tumor cells in patients with high levels of antibody.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA012582-14
Application #
3092576
Study Section
(SRC)
Project Start
1977-07-01
Project End
1987-03-31
Budget Start
1985-07-01
Budget End
1987-03-31
Support Year
14
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Dükel, Muzaffer; Streitfeld, W Scott; Tang, Tsz Ching Chloe et al. (2016) The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia. J Biol Chem 291:21541-21552
Kiyohara, Eiji; Hata, Keisuke; Lam, Stella et al. (2014) Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 1102:513-22
Greenberg, Edward S; Chong, Kelly K; Huynh, Kelly T et al. (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170-7
Chiu, Connie G; Nakamura, Yoshitaka; Chong, Kelly K et al. (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60:873-85
Faries, Mark B; Steen, Shawn; Ye, Xing et al. (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217:27-34; discussion 34-6
Kidner, Travis B; Morton, Donald L; Lee, Delphine J et al. (2012) Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716-20
Hoshimoto, Sojun; Shingai, Tatsushi; Morton, Donald L et al. (2012) Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26
Hoshimoto, Sojun; Kuo, Christine T; Chong, Kelly K et al. (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 132:1689-97
Faries, Mark B; Morton, Donald L (2012) Staging of regional nodes in pulmonary malignancies. Ann Surg Oncol 19:703-5
Hoshimoto, Sojun; Faries, Mark B; Morton, Donald L et al. (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62

Showing the most recent 10 out of 238 publications